Advanced

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

Lindemann, K.; Christensen, R. D.; Vergote, I.; Stuart, G.; Izquierdo, M. A.; Kaem, J.; Havsteen, H.; Eisenhauer, E.; Ridderheim, Mona LU and Lopez, A. B., et al. (2012) In Annals of Oncology 23(10). p.31-2613
Abstract
Background: The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel. Patients and methods: We carried out a prospectively randomized phase III study comparing carboplatin plus paclitaxel (TC; area under the curve 5 and 175 mg/m(2)) with the same combination and epirubicin (TEC; 75 mg/m(2) i.v.). Between March 1999 and August 2001, 887 patients with epithelial ovarian, tubal or peritoneal cancer International Federation of Gynecology and Obstetrics stages IIB-IV were randomized to receive either TC (442 patients) or TEC (445 patients). Results: Median time to progression was 16.4... (More)
Background: The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel. Patients and methods: We carried out a prospectively randomized phase III study comparing carboplatin plus paclitaxel (TC; area under the curve 5 and 175 mg/m(2)) with the same combination and epirubicin (TEC; 75 mg/m(2) i.v.). Between March 1999 and August 2001, 887 patients with epithelial ovarian, tubal or peritoneal cancer International Federation of Gynecology and Obstetrics stages IIB-IV were randomized to receive either TC (442 patients) or TEC (445 patients). Results: Median time to progression was 16.4 months in the TEC arm and 16.0 months in the TC arm (hazard ratio 0.99; 95% confidence interval [CI]: 0.9-1.2). Median overall survival time was 42.4 months for the TEC arm and 40.2 for the TC arm (hazard ratio 0.96; 95% CI: 0.8-1.1). Grade 3/4 hematologic toxic effects and most grade 3/4 non-hematologic toxic effects were more frequent in the TEC arm. Accordingly, a quality-of-life analysis showed inferiority of TEC versus TC. Conclusion: The addition of epirubicin to standard carboplatin and paclitaxel treatment did not improve survival in patients with advanced ovarian, tubal or peritoneal cancer. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
epirubicin, phase III study, platinum-based chemotherapy, ovarian, cancer, survival, toxicity
in
Annals of Oncology
volume
23
issue
10
pages
31 - 2613
publisher
Oxford University Press
external identifiers
  • wos:000309412700017
  • scopus:84867116493
ISSN
1569-8041
DOI
10.1093/annonc/mds060
language
English
LU publication?
yes
id
8d10aa43-27b0-4e42-8572-c6db7d1c4521 (old id 3187434)
date added to LUP
2012-12-03 06:56:24
date last changed
2017-04-23 03:51:07
@article{8d10aa43-27b0-4e42-8572-c6db7d1c4521,
  abstract     = {Background: The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel. Patients and methods: We carried out a prospectively randomized phase III study comparing carboplatin plus paclitaxel (TC; area under the curve 5 and 175 mg/m(2)) with the same combination and epirubicin (TEC; 75 mg/m(2) i.v.). Between March 1999 and August 2001, 887 patients with epithelial ovarian, tubal or peritoneal cancer International Federation of Gynecology and Obstetrics stages IIB-IV were randomized to receive either TC (442 patients) or TEC (445 patients). Results: Median time to progression was 16.4 months in the TEC arm and 16.0 months in the TC arm (hazard ratio 0.99; 95% confidence interval [CI]: 0.9-1.2). Median overall survival time was 42.4 months for the TEC arm and 40.2 for the TC arm (hazard ratio 0.96; 95% CI: 0.8-1.1). Grade 3/4 hematologic toxic effects and most grade 3/4 non-hematologic toxic effects were more frequent in the TEC arm. Accordingly, a quality-of-life analysis showed inferiority of TEC versus TC. Conclusion: The addition of epirubicin to standard carboplatin and paclitaxel treatment did not improve survival in patients with advanced ovarian, tubal or peritoneal cancer.},
  author       = {Lindemann, K. and Christensen, R. D. and Vergote, I. and Stuart, G. and Izquierdo, M. A. and Kaem, J. and Havsteen, H. and Eisenhauer, E. and Ridderheim, Mona and Lopez, A. B. and Hirte, H. and Aavall-Lundquvist, E. and Vrdoljak, E. and Green, J. and Kristensen, G. B.},
  issn         = {1569-8041},
  keyword      = {epirubicin,phase III study,platinum-based chemotherapy,ovarian,cancer,survival,toxicity},
  language     = {eng},
  number       = {10},
  pages        = {31--2613},
  publisher    = {Oxford University Press},
  series       = {Annals of Oncology},
  title        = {First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG},
  url          = {http://dx.doi.org/10.1093/annonc/mds060},
  volume       = {23},
  year         = {2012},
}